Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 8 | 2024 | 599 | 1.480 |
Why?
|
| Colorectal Neoplasms | 8 | 2024 | 974 | 1.380 |
Why?
|
| Adenocarcinoma | 10 | 2024 | 1182 | 1.300 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2022 | 110 | 1.000 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 28 | 0.880 |
Why?
|
| Lymphocytosis | 1 | 2022 | 12 | 0.820 |
Why?
|
| Gastritis | 1 | 2022 | 36 | 0.790 |
Why?
|
| Pathologists | 1 | 2021 | 30 | 0.710 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.700 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 94 | 0.690 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 5 | 0.690 |
Why?
|
| Observer Variation | 1 | 2021 | 615 | 0.640 |
Why?
|
| Carcinogenesis | 3 | 2019 | 216 | 0.630 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 24 | 0.590 |
Why?
|
| Atrial Septum | 1 | 2017 | 9 | 0.570 |
Why?
|
| Lipomatosis | 1 | 2017 | 9 | 0.570 |
Why?
|
| Hamartoma | 1 | 2017 | 35 | 0.560 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 288 | 0.550 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 20 | 0.520 |
Why?
|
| Immunohistochemistry | 8 | 2024 | 1806 | 0.400 |
Why?
|
| Appendiceal Neoplasms | 2 | 2024 | 31 | 0.400 |
Why?
|
| Aged | 20 | 2024 | 19424 | 0.390 |
Why?
|
| Male | 26 | 2024 | 42967 | 0.380 |
Why?
|
| Liver | 4 | 2022 | 1218 | 0.370 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 181 | 0.370 |
Why?
|
| Humans | 38 | 2024 | 90640 | 0.350 |
Why?
|
| Middle Aged | 22 | 2024 | 26347 | 0.340 |
Why?
|
| Female | 24 | 2024 | 46894 | 0.330 |
Why?
|
| Adult | 17 | 2024 | 26953 | 0.320 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 332 | 0.300 |
Why?
|
| Collagen | 3 | 2022 | 295 | 0.250 |
Why?
|
| Colitis | 2 | 2019 | 249 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2024 | 34 | 0.230 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2024 | 24 | 0.230 |
Why?
|
| Colonoscopy | 2 | 2024 | 281 | 0.230 |
Why?
|
| Siderosis | 1 | 2023 | 2 | 0.220 |
Why?
|
| Iron Overload | 1 | 2023 | 7 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 478 | 0.220 |
Why?
|
| Diet, Western | 2 | 2023 | 38 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 962 | 0.220 |
Why?
|
| Hepatitis | 1 | 2023 | 34 | 0.210 |
Why?
|
| Colorectal Surgery | 1 | 2023 | 22 | 0.210 |
Why?
|
| Colonic Polyps | 1 | 2024 | 132 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 48 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 201 | 0.210 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 11 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 151 | 0.210 |
Why?
|
| Plasmacytoma | 1 | 2022 | 34 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 39 | 0.200 |
Why?
|
| Gastrointestinal Tract | 2 | 2022 | 192 | 0.200 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 93 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 153 | 0.200 |
Why?
|
| Goblet Cells | 1 | 2022 | 20 | 0.200 |
Why?
|
| Atrophy | 1 | 2022 | 124 | 0.200 |
Why?
|
| Adenomatoid Tumor | 1 | 2021 | 1 | 0.190 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2021 | 7 | 0.190 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 23 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6816 | 0.190 |
Why?
|
| Esophageal Stenosis | 1 | 2021 | 26 | 0.190 |
Why?
|
| Appendix | 1 | 2021 | 31 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2021 | 258 | 0.180 |
Why?
|
| Intestinal Mucosa | 2 | 2024 | 807 | 0.180 |
Why?
|
| Portal Vein | 1 | 2021 | 122 | 0.180 |
Why?
|
| Mutation | 2 | 2024 | 4183 | 0.170 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.170 |
Why?
|
| Injections | 1 | 2020 | 116 | 0.170 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.170 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 120 | 0.170 |
Why?
|
| Buschke-Lowenstein Tumor | 1 | 2019 | 1 | 0.170 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.170 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2019 | 12 | 0.170 |
Why?
|
| Mentors | 1 | 2021 | 92 | 0.170 |
Why?
|
| Fibrosis | 1 | 2021 | 238 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 81 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2019 | 53 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2020 | 95 | 0.160 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 16 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 41 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 56 | 0.160 |
Why?
|
| Hyperplasia | 3 | 2024 | 153 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.150 |
Why?
|
| Colectomy | 1 | 2019 | 175 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 337 | 0.150 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 4 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 205 | 0.150 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 168 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 341 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 36 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 135 | 0.140 |
Why?
|
| Cetuximab | 1 | 2018 | 116 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 531 | 0.140 |
Why?
|
| Hypertrophy | 1 | 2017 | 67 | 0.140 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.140 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1549 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1362 | 0.140 |
Why?
|
| Camptothecin | 1 | 2018 | 197 | 0.140 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.140 |
Why?
|
| Endoscopy | 1 | 2020 | 353 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1066 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 298 | 0.130 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 2525 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 455 | 0.130 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2016 | 17 | 0.130 |
Why?
|
| Renin | 1 | 2016 | 67 | 0.130 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2016 | 22 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 419 | 0.130 |
Why?
|
| Defecation | 1 | 2016 | 23 | 0.130 |
Why?
|
| Rectal Diseases | 1 | 2016 | 23 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1179 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 80 | 0.130 |
Why?
|
| Choristoma | 1 | 2016 | 68 | 0.130 |
Why?
|
| Stomach | 1 | 2016 | 111 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1486 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 3813 | 0.120 |
Why?
|
| Rectum | 1 | 2016 | 149 | 0.120 |
Why?
|
| Diarrhea | 1 | 2016 | 178 | 0.120 |
Why?
|
| Pandemics | 1 | 2021 | 789 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 264 | 0.120 |
Why?
|
| Young Adult | 3 | 2024 | 6426 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 572 | 0.120 |
Why?
|
| Adolescent | 3 | 2024 | 9354 | 0.110 |
Why?
|
| Child | 2 | 2024 | 7219 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 414 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 179 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 1096 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 526 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 955 | 0.100 |
Why?
|
| Genomics | 1 | 2017 | 784 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 402 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1608 | 0.100 |
Why?
|
| Biopsy | 3 | 2021 | 1192 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 277 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2023 | 9330 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 376 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 760 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 8379 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2023 | 1095 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2342 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 222 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2020 | 548 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 280 | 0.070 |
Why?
|
| Colon | 2 | 2021 | 522 | 0.060 |
Why?
|
| Mice | 4 | 2023 | 11949 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1873 | 0.060 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2024 | 8 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2409 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2024 | 104 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 69 | 0.050 |
Why?
|
| Transferrins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 29 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 82 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 173 | 0.050 |
Why?
|
| Allografts | 1 | 2023 | 190 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2891 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2023 | 104 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 91 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 5583 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2021 | 90 | 0.050 |
Why?
|
| Esophagus | 1 | 2021 | 107 | 0.050 |
Why?
|
| Autopsy | 1 | 2021 | 125 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 313 | 0.040 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 82 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 27715 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 34 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 242 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 488 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 327 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 233 | 0.040 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 73 | 0.040 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 59 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 340 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 94 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 662 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3184 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 745 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 521 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 1084 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 3767 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 140 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1709 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 19 | 0.030 |
Why?
|
| Fumarates | 1 | 2016 | 19 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 705 | 0.030 |
Why?
|
| Losartan | 1 | 2016 | 30 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 176 | 0.030 |
Why?
|
| Intestines | 1 | 2019 | 416 | 0.030 |
Why?
|
| Amides | 1 | 2016 | 54 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1895 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 46 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2782 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1441 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 86 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 304 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 627 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 875 | 0.030 |
Why?
|
| Endosonography | 1 | 2016 | 100 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1170 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1855 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 984 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 498 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1747 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 872 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1305 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2019 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 493 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 806 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2338 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2042 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2020 | 765 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1286 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1800 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2019 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1583 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 693 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2609 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3278 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3698 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1725 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4348 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2337 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3431 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7142 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 2370 | 0.010 |
Why?
|